MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Ocular Therapeutix Inc

Closed

SectorHealthcare

9.45 4.3

Overview

Share price change

24h

Current

Min

8.98

Max

9.58

Key metrics

By Trading Economics

Income

-16M

-64M

Sales

-6.4M

11M

EPS

-0.372

Profit margin

-602.342

Employees

274

EBITDA

-20M

-64M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+93.41% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

154M

1.5B

Previous open

5.15

Previous close

9.45

News Sentiment

By Acuity

50%

50%

163 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Ocular Therapeutix Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jul 2025, 17:03 UTC

Major Market Movers

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2 Jul 2025, 15:18 UTC

Major Market Movers

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2 Jul 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Jul 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2 Jul 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2 Jul 2025, 21:01 UTC

Acquisitions, Mergers, Takeovers

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2 Jul 2025, 21:01 UTC

Acquisitions, Mergers, Takeovers

AT&T and TPG Close DIRECTV Transaction

2 Jul 2025, 20:26 UTC

Earnings

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2 Jul 2025, 20:22 UTC

Market Talk

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2 Jul 2025, 20:13 UTC

Market Talk

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2 Jul 2025, 19:09 UTC

Market Talk

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2 Jul 2025, 19:08 UTC

Market Talk

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2 Jul 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2 Jul 2025, 18:08 UTC

Market Talk

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2 Jul 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2 Jul 2025, 17:05 UTC

Acquisitions, Mergers, Takeovers

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2 Jul 2025, 17:04 UTC

Acquisitions, Mergers, Takeovers

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2 Jul 2025, 17:04 UTC

Acquisitions, Mergers, Takeovers

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2 Jul 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2 Jul 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2 Jul 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2 Jul 2025, 16:20 UTC

Market Talk

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

2 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

2 Jul 2025, 16:11 UTC

Market Talk

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2 Jul 2025, 16:09 UTC

Market Talk

Gold Futures Rise, Recouping Some Losses -- Market Talk

2 Jul 2025, 15:59 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2 Jul 2025, 15:17 UTC

Market Talk

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2 Jul 2025, 15:08 UTC

Market Talk

Luxury Sector Should Report a Slowdown -- Market Talk

2 Jul 2025, 15:00 UTC

Acquisitions, Mergers, Takeovers

Glencore: Merger of Viterra With Bunge Global Closed

Peer Comparison

Price change

Ocular Therapeutix Inc Forecast

Price Target

By TipRanks

93.41% upside

12 Months Forecast

Average 17.6 USD  93.41%

High 22 USD

Low 14 USD

Based on 11 Wall Street analysts offering 12 month price targets forOcular Therapeutix Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

11

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

6.97 / 7.62Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

163 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.